Literature DB >> 29974410

Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model.

Danqing Hu1, Hongwu Wang2, Hai Wang3, Yaqi Wang1, Xiaoyang Wan1, Weiming Yan1, Xiaoping Luo4, Qin Ning5.   

Abstract

OBJECTIVE: The relationship between chronic hepatitis B virus (HBV) infection and fatty liver in patients remains unclear. Although high-fat diets-induced hepatic steatosis was proved to reduce HBV replication in transgenic mice, the interplay between HBV and fatty liver in immunocompetent mouse model is yet to be elucidated. Here, we aimed to develop an effective animal model for intracellular HBV persistence combined with hepatic steatosis and to explore their interactions.
METHODS: FVB/N mice with HBV genotype B replicon DNA were established by hydrodynamic injection. Mice injected with HBV or control plasmid vectors were then randomized into NAFLD + HBV, HBV, NAFLD, and control groups and treated with a high-fat or standard diet for up to 14 weeks. The characteristics of NAFLD were evaluated by physical indices, liver function tests, glycolipid metabolism, and liver histopathological changes. Viral dynamics were also analyzed by HBV DNA and HBV-related antigens.
RESULTS: HBV clone persistently replicated in the livers of FVB/N mice, and hepatic steatosis was induced by a high-fat diet. The NAFLD and NAFLD + HBV groups shared similar physical features, glycolipid metabolism, liver function, and hepatic steatosis. Serum hepatitis B e antigen (HBeAg), hepatic hepatitis B s antigen (HBsAg),hepatitis B c antigen (HBcAg), and HBV DNA were decreased in the NAFLD + HBV group compared with those in the HBV group at the end of 14 weeks.
CONCLUSION: In an HBV-immunocompetent mouse model, non-alcoholic hepatic steatosis inhibited HBV replication, as indicated by the reduction of HBV DNA and HBV-related antigens. HBV replication did not alter lipid metabolism in mice.

Entities:  

Keywords:  Animal model; Hepatitis B virus; Lipid metabolism; Non-alcoholic fatty liver disease

Mesh:

Year:  2018        PMID: 29974410     DOI: 10.1007/s12072-018-9877-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  29 in total

Review 1.  Mouse models for therapeutic vaccination against hepatitis B virus.

Authors:  Claudia Dembek; Ulrike Protzer
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

2.  Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity.

Authors:  Laurentius A Lesmana; C Rinaldi Lesmana; Levina S Pakasi; Ening Krisnuhoni
Journal:  Acta Med Indones       Date:  2012-01

3.  Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection.

Authors:  Jun-ping Shi; Jian-gao Fan; Rui Wu; Xiao-qian Gao; Li Zhang; Hao Wang; Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2008-09       Impact factor: 4.029

4.  Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without.

Authors:  Chia-Ming Chu; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2012-08-18       Impact factor: 3.199

5.  Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells.

Authors:  Ying-Ju Li; Ping Zhu; Yu Liang; Wei-Guo Yin; Jian-Hua Xiao
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

6.  Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis.

Authors:  Chia-Chi Wang; Ching-Sheng Hsu; Chun-Jen Liu; Jia-Horng Kao; Ding-Shinn Chen
Journal:  J Gastroenterol Hepatol       Date:  2007-11-19       Impact factor: 4.029

7.  A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Authors:  Melissa A Cobleigh; Xin Wei; Michael D Robek
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

8.  Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir.

Authors:  Bahadır Ceylan; Ferhat Arslan; Ayşe Batırel; Muzaffer Fincancı; Cem Yardımcı; Esra Fersan; Esra Paşaoğlu; Mesut Yılmaz; Ali Mert
Journal:  Turk J Gastroenterol       Date:  2015-12-17       Impact factor: 1.852

9.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

10.  Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha.

Authors:  Kyeongjin Kim; Kook Hwan Kim; Hyeong Hoe Kim; Jaehun Cheong
Journal:  Biochem J       Date:  2008-12-01       Impact factor: 3.857

View more
  16 in total

1.  Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.

Authors:  Lu Wang; Yijin Wang; Shuhong Liu; Xiangwei Zhai; Guangde Zhou; Fengmin Lu; Jingmin Zhao
Journal:  J Gastroenterol       Date:  2019-05-27       Impact factor: 7.527

2.  Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress.

Authors:  Qichuang Liu; Maoyuan Mu; Huan Chen; Guoyuan Zhang; Yanqing Yang; Jun Chu; Ying Li; Fangwan Yang; Shide Lin
Journal:  Mol Cell Biochem       Date:  2021-05-13       Impact factor: 3.396

3.  Fatty liver checkmates hepatitis B virus.

Authors:  Gayatri Ramakrishna; Nirupma Trehanpati
Journal:  Hepatol Int       Date:  2018-10-12       Impact factor: 6.047

4.  Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.

Authors:  Lung-Yi Mak; Rex Wan-Hin Hui; James Fung; Fen Liu; Danny Ka-Ho Wong; Bofei Li; Ka-Shing Cheung; Man-Fung Yuen; Wai-Kay Seto
Journal:  Hepatol Int       Date:  2021-06-21       Impact factor: 6.047

5.  Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load.

Authors:  Noam Peleg; Assaf Issachar; Orly Sneh Arbib; Michal Cohen-Naftaly; Marius Braun; Moshe Leshno; Alon Barsheshet; Amir Shlomai
Journal:  JHEP Rep       Date:  2019-03-19

6.  Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index.

Authors:  Ta-Wei Liu; Chung-Feng Huang; Ming-Lun Yeh; Pei-Chien Tsai; Tyng-Yuan Jang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu
Journal:  BMJ Open Gastroenterol       Date:  2020-12

7.  Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis.

Authors:  Daixi Jiang; Can Chen; Xiaoxiao Liu; Chenyang Huang; Danying Yan; Xiaobao Zhang; Yuqing Zhou; Yushi Lin; Yiyi Zhou; Zhou Guan; Cheng Ding; Lei Lan; Changtai Zhu; Jie Wu; Lanjuan Li; Shigui Yang
Journal:  Ann Transl Med       Date:  2021-12

8.  Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study.

Authors:  Yi-Cheng Chen; Wen-Juei Jeng; Chao-Wei Hsu; Chun-Yen Lin
Journal:  BMC Gastroenterol       Date:  2020-05-12       Impact factor: 3.067

9.  Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.

Authors:  Won Kim
Journal:  Clin Mol Hepatol       Date:  2018-12-28

10.  How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?

Authors:  Jung Hwan Yu; Jin-Woo Lee
Journal:  Clin Mol Hepatol       Date:  2019-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.